Environment_technology

Hydrogen event - podcast replay

On Monday 22 June, Bryan, Garnier & Co hosted a virtual webinar about the Hydrogen market, attended by over 130 participants across Europe and the US, to explore the future of this very promising energy carrier. Key note speakers Mark Russell (CEO) and Dhillon Sandhu (Strategic Projects), Nikola Motor and Laurent Carme (CEO), McPhy discussed their vision of the future and why now is the time for hydrogen to realize its potential as the leading solution for the transition towards a carbon-free world.

Click here to listen to the podcast >>

 

 

DISCLAIMER

Bryan Garnier & Co, registered in France no. 452 605 512 is a MiFID branch of Bryan Garnier & Co Limited (a UK company registered under the number 03034095) and is authorized and regulated by the Financial Conduct  Authority and the Autorité des Marchés Financiers (AMF). Registered address: 26 avenue des Champs Elysées, Paris 75008.

This has been prepared solely for informational purposes, and is intended only for use by the designated recipient(s). This information was obtained from sources we believe to be reliable, but its accuracy is not guaranteed. All information is subject to change without notice. This does not constitute a solicitation or offer to buy or sell securities or any other instruments, or a recommendation with respect to any security or instrument mentioned herein. This is not a confirmation of terms of any transaction. No representations are made herein with respect to availability, pricing, or performance. Additional information available on request.
This recording should only be listened to by those persons to whom it is addressed and is not intended to be relied upon by any person without subsequent written confirmation of its contents. If you have received this information in error, please destroy it and delete it from your computer. Any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this recording is strictly prohibited. Please note that any views or opinions presented in this podcast are solely those of the participants and do not necessarily represent those of Bryan, Garnier & Co. Finally, the recipient should check this source and any attachments for the presence of viruses. Bryan, Garnier & Co accepts no liability for any damage caused by any virus transmitted by this communication.


olive oil and vinegar

Medical cannabis in Western Europe

In this paper, we explore the reasons behind the growth of cannabis as a therapeutic substance and we explore the dynamics and developments in European medical cannabis, with a particular focus on Germany, Europe’s leading cannabis market.

The global cannabis market is evolving from an illegal and mainly recreational market dominated by drug cartels to a legal medical and recreational market in the hands of public and private companies.

Western Europe boasts some of the world’s fastest-evolving and most significant opportunities in medical cannabis, with countries reassessing their restrictions as public support for legalization grows and commercial and social benefits become apparent.

Existing medical cannabis markets such as Germany, Italy and the Netherlands are expanding their programs whilst new medical markets like the UK, France and Spain are reviewing current legislation. And the seeds of a second wave of growth to allow recreational adult use of cannabis are being planted.

Western Europe is on track to become the world’s largest legal medical cannabis market over the next ten years, projected to be worth EUR15.3bn in 2029, up 60x from EUR250m in 2019. Germany, the leading European medical market, is expected to grow to EUR4.9bn by 2029 from EUR210m in 20191. In this paper, we examine the dynamics and developments in European medical cannabis, with a detailed look at the German market.

Click here to download the report >>